Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III randomized double-blind placebo-controlled trial of Wujia Yizhi Granules in mild to moderate Alzheimer's disease
CTR20242180Phase 3Active
- Sponsor
- Sichuan Jishengtang Pharmaceutical Co., Ltd.
- Start
- Jun 2024
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of Wujia Yizhi Granules in Alzheimer's disease (AD), sponsored by Sichuan Jishengtang Pharmaceutical Co., Ltd.. Started Jun 2024; status: active.
02
Drugs
Wujia Yizhi Granules
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on CTR20242180.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20242180.